Abstracts tagged "spondyloarthritis"

Abstract Number: 1434 • ACR Convergence 2024
Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
Léa Da silva¹, olivier Fakih¹, mickael chouk¹, delphine weil-verhoeven², DANIEL WENDLING³, CLEMENT PRATI⁴ and FRANK VERHOEVEN¹, ¹Service de rhumatologie, CHU de Besancon, Besançon, France, ²Service d'hépatologie, CHU de Besancon, Besançon, France, ³University Hospital, Besançon, France, ⁴Service de Rhumatologie, centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, France
Background/Purpose: The management of axial spondyloarthritis (axSpA) comorbidities includes the metabolic syndrome (2). The latter includes steatotic liver disease (SLD) (3), which is present in…
Abstract Number: 1481 • ACR Convergence 2024
Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
Atul Deodhar¹, Iain McInnes², Xenofon Baraliakos³, Alice Gottlieb⁴, Uta Kiltz⁵, Stefan Schreiber⁶, Braja Gopal Sahoo⁷, Weibin Bao⁸, Corine Gaillez⁹, Mercedes Bustamante⁹ and Philip Mease¹⁰, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ⁴Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁶University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany, ⁷Novartis Healthcare Private Limited, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Secukinumab, a fully human anti-interleukin (IL)-17A monoclonal antibody, is approved for multiple immunological disorders, including moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), axial spondyloarthritis…
Abstract Number: 2156 • ACR Convergence 2024
Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Alexis Ogdie⁴, Michael Weisman⁵, John Reveille⁶ and Charles Green², ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Stanford University, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: IInflammatory back pain (IBP) has clinical features that distinguish it from other back pain etiologies. While there are established IBP criteria, in different subpopulations…
Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Iain McInnes¹, Laura Coates², Philip Mease³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Lihi Eder⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Eva Cullen⁹, Kristian Reich⁹, Christopher Ritchlin¹⁰ and Joseph F. Merola¹¹, ¹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵University of California San Diego, La Jolla, CA, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…
Abstract Number: 0235 • ACR Convergence 2024
Spine Structural Lesions in Ankylosing Spondylitis: Comparison Between Radiographic (RASSS) and Opportunistic Thoraco-abdomino-pelvic CT Assessment
Caroline Morizot¹, Inès Favre-Felix², Andréa Mennini³, Elodie Bauer³, Isabelle Chary-Valckenaere⁴ and Damien Loeuille⁵, ¹Nancy University hospital, Nancy, France, ²Nancy university, Vandœuvre-lès-Nancy, France, ³CHRU Nancy, Nancy, France, ⁴Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁵Phd, Nancy Vandoeuvre, Lorraine, France
Background/Purpose: The aim of this study is to evaluate the prevalence and severity of spinal structural lesions on radiograph versus opportunistic thoraco-abdomino-pelvic CT (TAP CT)…
Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Nelly Ziade¹, Sherif Gamal², Maroun Aoun³, Ihsane Hmamouchi⁴, Clementina López Medina⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²Cairo University, Cairo, Egypt, ³Saint Joseph University, Beirut, Lebanon, ⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
Abstract Number: 0567 • ACR Convergence 2024
Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Pankaj Sharma¹, Fatemeh Navid¹, Norman Watts¹, Stephen Brooks² and Robert Colbert², ¹National Institutes of Health, Bethesda, MD, ²NIH/NIAMS, Bethesda, MD
Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
Abstract Number: 0819 • ACR Convergence 2024
The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis
Denis Poddubnyy¹, Xenofon Baraliakos², Victoria Navarro Compán³, Murat Torgutalp⁴ and Desiree van der Heijde⁵, and ASAS Difficult-to-Manage Axial Spondyloarthritis Task Force, ¹Charite-Universitatsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁴Charite Universitatsmedizin - Berlin, Berlin, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Non-response to standard treatments represents a management challenge in axial Spondyloarthritis (axSpA). The Assessment of SpondyloArthritis international Society (ASAS) seeks to define 'difficult-to-manage axSpA'…
Abstract Number: 1435 • ACR Convergence 2024
Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment
Seong-Hyeok Bak, Kyung-Ann Lee, Eunsun Oh, Hyun-Sook Kim and Seunghyun Kim, Soonchunhyang University Seoul Hospital, seoul, Republic of Korea
Background/Purpose: Axial spondyloarthritis (axSpA) is a group of related inflammatory diseases characterized by enthesitis, synovitis, and osteitis. The assessment of axial enthesitis in the pelvis…
Abstract Number: 1482 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Atul Deodhar¹, Eva Dokoupilova², Cynthia Vizcaya³, Reema Sutariya⁴, Weibin Bao⁴, Karen Kapur³, Susanne Rohrer³ and Alan Kivitz⁵, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Altoona Center for Clinical Research, Duncansville, PA

Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
Abstract Number: 2157 • ACR Convergence 2024
Dimensionality of Inflammatory Back Pain Criteria in the US Population
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Alexis Ogdie⁴, Michael Weisman⁵, John Reveille⁶ and Charles Green², ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Stanford University, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: The evaluation of axial spondyloarthritis relies on capturing various inflammatory back pain (IBP) features, represented in IBP criteria. This study examines the dimensionality of…
Abstract Number: 2638 • ACR Convergence 2024
Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
Andre Lucas Ribeiro¹, Sibel Aydin², Gurjit Kaeley³, Fahmeen Afgani⁴, Catherine Bakewell⁵, Marcos Rosemffet⁶, Minna Kohler⁷, Amir Haddad⁸, Maria S. Stoenoiu⁹, Ari Polachek¹⁰, josefina marin¹¹, Arnon Katz¹² and Lihi Eder¹³, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²University of Ottawa - Ottawa, Ottawa, ON, Canada, ³UF COM-J, Ponte Vedra Beach, FL, ⁴Women's College Hospital, Toronto, Canada, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁷Massachusetts General Hospital, Boston, MA, ⁸Carmel Medical Centre, Haifa, Israel, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, ¹¹Hospital Italiano de Buenos Aires, buenos aires, Argentina, ¹²GRAPPA - Patient Research Partner, Haifa, Israel, ¹³University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Nelly Ziade¹, Ihsane Hmamouchi², Clementina López Medina³, Maroun Aoun⁴, Sherif Gamal⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²International University of Rabat, Rabat, Morocco, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Saint Joseph University, Beirut, Lebanon, ⁵Cairo University, Cairo, Egypt, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].